Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours

Inclusion Criteria: 1. Voluntarily sign the informed consent form (ICF); 2. Male or female, ≥ 18 years and ≤ 75 years old; 3. Survival duration more than 3 months; 4. ECOG score ≤ 1 point; 5. histologically or cytologically confirmed diagnosis of advanced malignant solid tumour； 6. At least one measurable tumor lession according to RECIST v1.1; 7. Adequate organ and bone marrow function. Exclusion Criteria: 1. Has participated in another clinical study within 4 weeks prior to the first dose; 2. Has previously received other immunotherapies other than PD-(L)1 inhibitors； 3. Other malignancies diagnosed within 5 years prior to the enrollment; 4. Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases; 5. Significant bleeding risk; 6. Presence of pleural effusion, peritoneal effusion, or ascites; 7. Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment； 8. History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs; 9. Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence; 10. History of severe allergies, severe drug allergies (including unapproved investigational drugs); 11. History of organ transplantation or stem cell transplantation; 12. Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study; 13. Pregnant or breastfeeding female.